India, Feb. 14 -- Biotechnology firm CSL Ltd. (CSL.AX,CMXHF.PK) and sa-mRNA pioneer Arcturus Therapeutics Ltd. (ARCT) announced Friday that the European Commission has granted marketing authorization for KOSTAIVE (ARCT-154), a self-amplifying mRNA COVID-19 vaccine, for individuals 18 years and older.
KOSTAIVE is the first sa-mRNA COVID-19 vaccine to receive approval from the European Commission. KOSTAIVE is currently marketed in Japan against COVID-19.
KOSTAIVE represents a significant advancement in vaccine technology, demonstrating superior immunogenicity and antibody persistence for up to 12 months post-vaccination compared to conventional mRNA COVID-19 vaccines in clinical trials.
The European Commission approval follows a positive o...